Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.
Petracci E, Scarpi E, Passardi A, Biggeri A, Milandri C, Vecchia S, Gelsomino F, Tassinari D, Tamberi S, Bernardini I, Accettura C, Frassineti GL, Amadori D, Nanni O. Petracci E, et al. Among authors: amadori d. Ther Adv Med Oncol. 2020 Jul 23;12:1758835920937427. doi: 10.1177/1758835920937427. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32754229 Free PMC article.
Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A, Scarpi E, Tamberi S, Cavanna L, Tassinari D, Fontana A, Pini S, Bernardini I, Accettura C, Ulivi P, Frassineti GL, Amadori D. Passardi A, et al. Among authors: amadori d. PLoS One. 2015 Aug 5;10(8):e0134732. doi: 10.1371/journal.pone.0134732. eCollection 2015. PLoS One. 2015. PMID: 26244985 Free PMC article. Clinical Trial.
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
Passardi A, Scarpi E, Cavanna L, Dall'Agata M, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Brandes AA, Tenti E, Vespignani R, Frassineti GL, Amadori D, De Giorgi U. Passardi A, et al. Among authors: amadori d. Oncotarget. 2016 May 31;7(22):33210-9. doi: 10.18632/oncotarget.8901. Oncotarget. 2016. PMID: 27120807 Free PMC article. Clinical Trial.
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.
Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Passardi A, et al. Among authors: amadori d. Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9. Sci Rep. 2017. PMID: 28874797 Free PMC article. Clinical Trial.
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial.
Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I, Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL, Amadori D, Passardi A. Casadei Gardini A, et al. Among authors: amadori d. Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi: 10.2147/OTT.S166614. eCollection 2018. Onco Targets Ther. 2018. PMID: 30214231 Free PMC article.
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Frassineti GL, Amadori D. Passardi A, et al. Among authors: amadori d. Ann Oncol. 2015 Jun;26(6):1201-1207. doi: 10.1093/annonc/mdv130. Epub 2015 Mar 3. Ann Oncol. 2015. PMID: 25735317 Free article. Clinical Trial.
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Passardi A, Cecconetto L, Dall'agata M, Dazzi C, Pasquini E, Oliverio G, Zumaglini F, Zoli W, Nanni O, Milandri C, Frassineti GL, Amadori D. Passardi A, et al. Among authors: amadori d. J Transl Med. 2008 Oct 31;6:65. doi: 10.1186/1479-5876-6-65. J Transl Med. 2008. PMID: 18976450 Free PMC article. Clinical Trial.
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.
Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P, Bravaccini S, Calistri D, Saragoni L, Casadei Gardini A, Ragazzini A, Frassineti GL, Amadori D, Passardi A. Ulivi P, et al. Among authors: amadori d. J Transl Med. 2012 May 8;10:87. doi: 10.1186/1479-5876-10-87. J Transl Med. 2012. PMID: 22569004 Free PMC article.
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D. Ulivi P, et al. Among authors: amadori d. J Transl Med. 2015 Aug 11;13:258. doi: 10.1186/s12967-015-0619-5. J Transl Med. 2015. PMID: 26259598 Free PMC article. Clinical Trial.
518 results